Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

被引：10
|
作者：
Leonardi, Craig L. [1 ]
机构：
[1] St Louis Univ, Cent Dermatol, Dermatol, St Louis, MO 63103 USA
来源：
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2016年 / 35卷
关键词：
IL-12/23; inhibitors; IL-17/IL-17A inhibitors; IL-23; PLACEBO-CONTROLLED TRIAL; TO-SEVERE PSORIASIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; IL; 12/23; AGENTS; DOUBLE-BLIND; CARDIOVASCULAR EVENTS; PLAQUE PSORIASIS; METAANALYSES; USTEKINUMAB; SAFETY;
D O I：
10.12788/j.sder.2016.021
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
The anti-tumor necrosis factor (TNF)-alpha agents represent the second generation of psoriasis therapy. Research has produced a third generation of biologic treatments, some of which offer greater efficacy than the TNF-alpha inhibitors. This article reviews the data documenting the efficacy and safety of three types of biologics. (C) 2016 published by Frontline Medical Communications
引用
收藏
页码：S74 / S77
页数：4
相关论文
共 50 条
  • [41] A polymorprism in the 3′UTR of the IL-12 p40 gene correlates with plasma IL-12 secretion in burn patients.
    Rivera-Chavez, FA
    Cusano, A
    Minei, JP
    Wheeler, HT
    Horton, JW
    SHOCK, 2004, 21 : 84 - 84
  • [42] The imbalance of mucosal expression of IL-12 (p40) and a putative IL-12 (P40) receptor antagonist (EBI3) is associated with the onset of colitis in the IL-2 deficient mouse.
    Stevens, AC
    Christ, AD
    Birkenbach, M
    Blumberg, RS
    GASTROENTEROLOGY, 1996, 110 (04) : A1020 - A1020
  • [43] IL-12 p40 prevents the development of chronic enterocolitis in IL-10-deficient rice
    Shiraki, M
    Aihara, H
    Kinouchi, Y
    Matsumoto, K
    Takahashi, S
    Shimosegawa, T
    GASTROENTEROLOGY, 2003, 124 (04) : A494 - A494
  • [44] IL-12 p40 prevents the development of chronic enterocolitis in IL-10-deficient mice
    Shiraki, M
    Aihara, H
    Kinouchi, Y
    Takahashi, S
    Oki, M
    Noguchi, M
    Takahashi, K
    Miyazaki, J
    Shimosegawa, T
    LABORATORY INVESTIGATION, 2004, 84 (11) : 1491 - 1500
  • [45] Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis
    Shigehara, K
    Shijubo, N
    Ohmichi, M
    Kamiguchi, K
    Takahashi, R
    Morita-Ichimura, S
    Ohchi, T
    Tatsuno, T
    Hiraga, Y
    Abe, S
    Sato, N
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (01): : 152 - 157
  • [46] The Role of IL-17A in Psoriasis Pathogenesis and Treatment
    Krueger, James G.
    CYTOKINE, 2017, 100 : 24 - 24
  • [47] COST-PER-RESPONDER ANALYSIS OF BIMEKIZUMAB (IL17A/F INHIBITOR) AGAINST IL-17A, IL-12/23 AND IL-23 INHIBITORS FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN FINLAND
    Veijalainen, L.
    Lyris, N.
    Elo, P. J. K.
    Ferguson, A.
    Willems, D.
    VALUE IN HEALTH, 2024, 27 (12)
  • [48] Reciprocal regulation of IL-12 p40 versus IL-12 p70 production in dendritic cells.: Regulation of IL-12 subunits by PGE2 and IL-4.
    Kalinski, P
    Schuitemaker, J
    Kapsenberg, ML
    JOURNAL OF LEUKOCYTE BIOLOGY, 1998, : 79 - 79
  • [49] An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis
    Toichi, Eiko
    Torres, Gisela
    McCormick, Thomas S.
    Chang, Timothy
    Mascelli, Mary Ann
    Kauffman, Catharine L.
    Aria, Nancy
    Gottlieb, Alice B.
    Everitt, Daniel E.
    Frederick, Bart
    Pendley, Charles E.
    Cooper, Kevin D.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (07): : 4917 - 4926
  • [50] CPG ODN-mediated regulation of IL-12 p40 transcription
    Takeshita, F
    Klinman, DM
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2000, 30 (07) : 1967 - 1976
12345